Back

Remnant cholesterol predicts major cardiovascular events in cardiovascular disease patients with NAFLD

28 August 2023 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: lipids (5) Lipids ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Barbara Larcher

0012o00003HdGn8AAF (VIVIT), Feldkirch (Austria)

8 More presentations in this session

Presentation thumbnail
Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
Early diagnosis and treatments in childhood are associated with better prognosis in patients with familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
L-shaped association of lipoprotein(a) on long-term bleeding risk in patients with coronary heart disease: insight from a multicenter cohort in Asia
Doctor P. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Survey on lipid management in cardiovascular primary prevention: do physicians follow the guidelines?
Professor M. Alami (Casablanca, MA)
Abstract Slides Video
Presentation thumbnail
Remnant cholesterol in atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Doctor D. Delialis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention: lipids (5)

The Event

Event poster

ESC Congress 2023

28 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Remnant cholesterol predicts major cardiovascular events in coronary artery disease patients with NAFLD
thumbnail
Congress Presentation
Long-term prognostic impact of remnant cholesterol distribution after percutaneous coronary intervention and coronary artery bypass graft: insights from a nationwide cohort
thumbnail
Congress Presentation
Composition of non-HDL cholesterol and residual cardiovascular risk in secondary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources